3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2/3
1
Status
Terminated
2
Not yet recruiting
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Genitourinary
2
Conditions
Urinary Bladder Neoplasms
6
Colorectal Neoplasms
4
Carcinoma, Transitional Cell
4
Non-Muscle Invasive Bladder Neoplasms
3
Neoplasm Metastasis
3
Colonic Neoplasms
3
Anus Neoplasms
3
Sarcoma
2
Rectal Neoplasms
2
Pancreatic Neoplasms
2
Neoplasms
2
Carcinoma in Situ
2
Virus Diseases
1
Urologic Neoplasms
1
Urologic Diseases
1
Urogenital Neoplasms
1
Urinary Bladder Diseases
1
Neoplasms by Site
1
Neoplasm Recurrence, Local
1
Nasopharyngeal Carcinoma
1
Mycobacterium Infections
1
Head and Neck Neoplasms
1
Epstein-Barr Virus Infections
1
Disease
1
Dermatitis
1
Carcinoma, Hepatocellular
1
Adenoviridae Infections
1
Interventions
valrubicin
2
Mitomycin
2
Gemcitabine
2
enfortumab vedotin
1
durvalumab
1
advexin
1
Surveys and Questionnaires
1
Standard of Care
1
Oncolytic Virotherapy
1
Nivolumab
1
Interferons
1
Cystoscopy
1
Biopsy
1
ALT-801
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Terminated
×
Carcinoma in Situ
×
Mitomycin
×
Clear all
NCT01438112
2021-04-14
BOND
CG Oncology, Inc.
Phase 2/3
Terminated
22 enrolled
NCT01200992
2017-08-24
EMBARC-RF
Bioniche Life Sciences Inc.
Phase 3
Terminated
84 enrolled
7 charts